OM:BACTI B

Stock Analysis Report

Executive Summary

Bactiguard Holding AB (publ), a medtech company, engages in the research and development, production, marketing, and sale of infection prevention solutions, primarily in Sweden and Malaysia.


Snowflake Analysis

Adequate balance sheet with acceptable track record.

Share Price & News

How has Bactiguard Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BACTI B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

BACTI B

13.5%

SE Medical Equipment

11.7%

SE Market


1 Year Return

263.0%

BACTI B

10.4%

SE Medical Equipment

-9.7%

SE Market

Return vs Industry: BACTI B exceeded the Swedish Medical Equipment industry which returned 10.4% over the past year.

Return vs Market: BACTI B exceeded the Swedish Market which returned -9.7% over the past year.


Shareholder returns

BACTI BIndustryMarket
7 Day0%13.5%11.7%
30 Day50.6%-3.1%-16.3%
90 Day60.4%-13.3%-21.1%
1 Year263.0%263.0%12.2%10.4%-7.1%-9.7%
3 Year684.0%684.0%34.0%18.8%2.2%-12.9%
5 Year846.4%846.4%29.6%7.0%10.1%-13.0%

Price Volatility Vs. Market

How volatile is Bactiguard Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bactiguard Holding undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BACTI B (SEK132.5) is trading below our estimate of fair value (SEK271.96)

Significantly Below Fair Value: BACTI B is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BACTI B is poor value based on its PE Ratio (271.4x) compared to the Medical Equipment industry average (50.8x).

PE vs Market: BACTI B is poor value based on its PE Ratio (271.4x) compared to the Swedish market (14.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BACTI B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BACTI B is overvalued based on its PB Ratio (11.4x) compared to the SE Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Bactiguard Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bactiguard Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bactiguard Holding performed over the past 5 years?

57.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BACTI B has high quality earnings.

Growing Profit Margin: BACTI B became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BACTI B has become profitable over the past 5 years, growing earnings by 57.6% per year.

Accelerating Growth: BACTI B has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BACTI B has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).


Return on Equity

High ROE: BACTI B's Return on Equity (4.2%) is considered low.


Next Steps

Financial Health

How is Bactiguard Holding's financial position?


Financial Position Analysis

Short Term Liabilities: BACTI B's short term assets (SEK97.3M) exceed its short term liabilities (SEK66.9M).

Long Term Liabilities: BACTI B's short term assets (SEK97.3M) do not cover its long term liabilities (SEK187.8M).


Debt to Equity History and Analysis

Debt Level: BACTI B's debt to equity ratio (32.8%) is considered satisfactory.

Reducing Debt: BACTI B's debt to equity ratio has reduced from 44.1% to 32.8% over the past 5 years.


Balance Sheet

Inventory Level: BACTI B has a low level of unsold assets or inventory.

Debt Coverage by Assets: BACTI B's debt is not covered by short term assets (assets are 0.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BACTI B is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: BACTI B is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is Bactiguard Holding's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BACTI B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BACTI B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BACTI B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BACTI B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BACTI B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average board tenure


CEO

Cecilia Edström (53yo)

no data

Tenure

Ms. Cecilia Edström serves as Chief Executive Officer at Bactiguard Holding AB (publ) since February 2020. Ms. Edström served as Chief Financial Officer of Bactiguard Holding AB (publ) since 2018 until Feb ...


Board Members

NamePositionTenureCompensationOwnership
Thomas von Koch
Director0.83yrno datano data
Kenneth Chien
Chairman of the Scientific Advisory Boardno datano datano data
Christian Kinch
Directorno datano datano data
Mia Arnhult
Independent Director6.17yrskr300.00k0.15% SEK6.6m
Kwong-Hang Tam
Member of the Scientific Advisory Boardno datano datano data
Staffan Holmin
Member of the Scientific Advisory Boardno datano datano data
David Finn
Member of the Scientific Advisory Boardno datano datano data
Jan Stahlberg
Chairman of the Board1.83yrsno data10% SEK441.2m
Anna Martling
Director0.83yrno datano data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Board: BACTI B's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BACTI B insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bactiguard Holding AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bactiguard Holding AB (publ)
  • Ticker: BACTI B
  • Exchange: OM
  • Founded: 2005
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr4.413b
  • Shares outstanding: 33.30m
  • Website: https://www.bactiguard.se

Number of Employees


Location

  • Bactiguard Holding AB (publ)
  • PO Box 15
  • Tullinge
  • Stockholm County
  • 146 21
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BACTI BOM (OMX Nordic Exchange Stockholm)YesB SharesSESEKJun 2014
0QV2LSE (London Stock Exchange)YesB SharesGBSEKJun 2014

Biography

Bactiguard Holding AB (publ), a medtech company, engages in the research and development, production, marketing, and sale of infection prevention solutions, primarily in Sweden and Malaysia. Its infection prevention solutions prevent healthcare associated infections caused by medical devices. The company’s portfolio covers medical devices in three application areas, including the urinary tract, the blood stream, and the respiratory tract. Its product portfolio consists of indwelling Foley catheters that are used for drainage and irrigation of the bladder or for the collection and measurement of patient urine; endotracheal tubes for use in airway management by oral or nasal intubation of the trachea; and central venous catheters, which is used to administer drugs and intravenous solutions, sample blood, and for blood pressure monitoring. The company markets its products through distributors in approximately 40 countries. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 23:20
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.